- Home
- DMA vs MGNX Comparison
DMA vs MGNX Comparison
Compare DMA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- MGNX
- Stock Information
- Founded
- DMA 2011
- MGNX 2000
- Country
- DMA United States
- MGNX United States
- Employees
- DMA N/A
- MGNX N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- MGNX Health Care
- Exchange
- DMA Nasdaq
- MGNX Nasdaq
- Market Cap
- DMA 70.8M
- MGNX 70.3M
- IPO Year
- DMA N/A
- MGNX 2013
- Fundamental
- Price
- DMA $7.99
- MGNX $1.71
- Analyst Decision
- DMA
- MGNX Hold
- Analyst Count
- DMA 0
- MGNX 10
- Target Price
- DMA N/A
- MGNX $6.83
- AVG Volume (30 Days)
- DMA 34.6K
- MGNX 1.1M
- Earning Date
- DMA 01-01-0001
- MGNX 05-08-2025
- Dividend Yield
- DMA 2.04%
- MGNX N/A
- EPS Growth
- DMA N/A
- MGNX N/A
- EPS
- DMA N/A
- MGNX N/A
- Revenue
- DMA N/A
- MGNX $149,962,000.00
- Revenue This Year
- DMA N/A
- MGNX N/A
- Revenue Next Year
- DMA N/A
- MGNX $80.86
- P/E Ratio
- DMA N/A
- MGNX N/A
- Revenue Growth
- DMA N/A
- MGNX 155.26
- 52 Week Low
- DMA $4.78
- MGNX $0.99
- 52 Week High
- DMA $8.00
- MGNX $16.59
- Technical
- Relative Strength Index (RSI)
- DMA 45.67
- MGNX 57.37
- Support Level
- DMA $7.71
- MGNX $1.10
- Resistance Level
- DMA $8.05
- MGNX $1.34
- Average True Range (ATR)
- DMA 0.33
- MGNX 0.16
- MACD
- DMA 0.03
- MGNX 0.09
- Stochastic Oscillator
- DMA 65.60
- MGNX 90.00
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.